Study finds significant variation in biomarker test utilization and treatment for non–small-cell lung cancer – News-Medical.Net

Biomarker testing surveys specific disease-associated molecules to predict treatment response and disease progression; however its use has complicated the diagnosis of non-small-cell lung cancer (NSCLC). In a new study in TheJournal of Molecular Diagnosis, published by Elsevier, investigators provide for the first time a complete overview of biomarker testing, spanning multiple treatment lines, in a single cohort of patients.
Using exploratory data analysis and process-mining techniques in a real-world…

Click here to view the original article.